Diabetic Kidney Disease

John Cijiang He

DOI: https://doi.org/10.1093/med/9780190611620.003.0028

2019-02-01

Abstract:Diabetic kidney disease (DKD) is the most common cause of ESRD in USA as well as in the world. The incidence and the prevalence of DKD have been increasing regardless of current intervention. The pathology of DKD is characterized by accumulation of extracellular matrix in GBM and mesangial area. The pathogenesis of DKD is multi-factorial including genetic, metabolic, and hemodynamic changes, which lead to activation of oxidative stress, inflammation, and fibrosis pathways in the diabetic kidney. Clinically, patients with DKD presents with glomerular hyperfiltration at early stage, then microalbuminuria, macroalbuminuria, and ESRD. However, the disease progression varies greatly among individual patients. Treatment of DKD is limited to hyperglycemic and blood pressure control and use of RAS blockade. Several new drugs such as SGLT2 inhibitors have been on phase 3 clinical trials but research is required to develop more effective drugs to treat DKD.